Multidisciplinary MANAGEMENT OF EsophaGO-Gastric CARCINOMA

SATURDAY, OCTOBER 13, 2018

Glen Site Hospital MCGILL UNIVERSITY HEALTH CENTRE

amphitheatre ES1. 1129MONTREAL , CANADA

Div i s ion ofrad iat ion oncology

D iv i s ion ofmed i c al oncology

D iv i s ion ofgastroenterolOgy

D iv i s ion ofThorac i c Surgery

2 ANNUAL SYMPOSIUM ON GASTRO -INTESTINALCANCERS

nd

W E LCO M E M E S S AG E

Welcome to the 2nd Annual Symposium on Upper Gastro-Intestinal Cancers. This symposium aims to gather gastroenterologists, medical oncologists, radiation oncologists, surgeons, researchers and other healthcare professionals from across the world, in order to share their expertise on esophago-gastric carcinomas.

Following the success of last year’s event, it is our hope that this symposium will invite open discussion on innovative approaches to clinical teaching and surgical ideas, as well as spark future research collaborations, in order to make a difference in the diagnosis and treatment of esophageal and gastric cancer patients.

DR THIERRY ALCINDOR M E D I C A L O N C O L O G I S T - M C G I L L U N I V E R S I T Y DR JOANNE ALFIERI R A D I A T I O N O N C O L O G I S T - M C G I L L U N I V E R S I T Y DR LORENZO FERRI T H O R A C I C S U R G E O N - M C G I L L U N I V E R S I T Y DR SERGE MAYRAND G A S T R O E N T E R O L O G I S T - M C G I L L U N I V E R S I T Y

CO M M I T T E E M E M B E R S

T H A N K YO U TO O U R S P O N S O R S

VISITING PROFESSORS

DR NASSER ALTORKIS U R G E O N CO R N E L L U N I V E R S I T Y, N E W YO R K

Dr. Nasser Altorki is the Chief of the division of thoracic surgeon at Weill Cornell Medicine at NewYork-Presbyterian Hospital. Dr. Altorki’s expertise includes lung cancer immunotherapy and prevention; esophageal diseases; the biology, staging and therapy for esophageal carcinoma; mediastinal tumors; thymomas and clinical trials in lung and esophageal cancer. His surgical interests focus on minimally invasive surgery for lung and esophageal diseases. Nasser is also the Leader of the Solid Tumor program at the Sara and Edward Meyer Cancer Center of Weill Cornell Medicine.

Beyond his expertise in the surgical treatment of lung cancer and other chest malignancies, Dr. Altorki has a long-standing interest in studying the immune landscape as well as immunotherapy for early stage lung cancer. In 2007, Nasser also established the Neuberger Berman Lung Cancer Research Program at Weill Cornell Medicine. Since inception, the program has expanded to include two principal investigators, several post-doctoral scientists and a number of graduate students. The program also includes a world-class biobank of tissues from patients with early lung cancer linked to a companion annotated clinical database that includes nearly 4,000 patients with lung cancer.

DR TANIOS BEKAII-SAABM E D I C A L O N CO LO G I S T M AYO C L I N I C , A R I ZO N A

Tanios Bekaii-Saab, MD, is a professor of medicine at the Mayo Clinic College of Medicine and Science, co-leader of the Gastro-intestinal Cancer Program at the Mayo Clinic Cancer Center, medical director of the Cancer Clinical Research Office, and a senior associate consultant in the Division of Hematology/Oncology in the Department of Internal Medicine at the Mayo Clinic in Phoenix, Arizona, USA.

Dr. Bekaii-Saab earned his medical degree from the American University of Beirut in Lebanon and completed a residency in internal medicine at Indiana University Medical Center in Indianapolis, Indiana, USA. He then completed fellowships in clinical pharmacology and experimental therapeutics and hematology/oncology at Tufts University/New England Medical Center in Boston, Massachusetts, USA.

Dr Bekaii-Saab has authored or co-authored more than 350 peer reviewed publications, abstracts, and book chapters, including papers in such journals as Lancet Oncology, Journal of Clinical Oncology, JAMA, Journal of the National Cancer Institute, Annals of Oncology, and Clinical Cancer Research.

DR WAYNE HOFSTETTERS U R G E O N M D A N D E R S O N C A N C E R C E N T E R H O U S TO N

Wayne L. Hofstetter, M.D., is currently Professor and Deputy Chair in the Department of Thoracic and Cardiovascular Surgery and serves as Director of the Esophageal Surgery Program.

A graduate of the University of Southern California Medical School, Dr. Hofstetter focused on thoracic surgical disease, completing fellowships in esophageal and foregut surgeries at the University of Southern California, and then thoracic oncology at M. D. Anderson Cancer Center. Broadly trained as a cardiothoracic surgeon and thoracic oncologist at the Texas Heart Institute, he now devotes a great deal of his work to esophageal cancer and lung cancer. At MD Anderson, he formed a strong network of clinicians with specific interests in esophageal diseases. A multidisciplinary group emerged under his able leadership, and together, physicians from other specialties like Gastrointestinal Medical Oncology, Radiation Oncology, and Gastroenterology collaborate closely to treat esophageal cancer patients.

Dr. Hofstetter is a leading proponent of surgical and multidisciplinary approaches to esophageal cancer and minimally invasive approaches to lung cancer, bringing to the institution his unique clinical skills in MIS approaches to thoracic surgery.

DR STEVEN LINR A D I AT I O N O N CO LO G I S T M D A N D E R S O N C A N C E R C E N T E R H O U S TO N

I am an Associate Professor in Radiation Oncology at MD Anderson Cancer Center. I received my M.D./Ph.D. degrees in the Medical Scientist Training Program at The University of California Irvine Medical School and completed residency at Johns Hopkins. One of my primary clinical research interest focuses on ways to enhance radiotherapy cures in esophageal cancer. This can incorporate the use of advanced radiation techniques to limit the exposure of normal tissue and reduce the morbidity of treatment. The clinical benefit of advanced radiation technologies to improve outcomes in esophageal cancer has been demonstrated from single institutional datasets to large population or hospital-based databases.

I am currently PI of a Phase IIB randomized trial comparing Proton Beam Therapy (PBT) vs. Intensity Modulated Radiation Therapy (IMRT) in esophageal cancer. This is currently being developed as a NRG Phase III randomized trial (GI1543) for which I will serve as the national PI.

DR JOHN REYNOLDSS U R G E O N T R I N I T Y CO L L E G E D U B L I N , I R E L A N D

Professor Reynolds is Professor of Clinical Surgery at the St. James’s Hospital and Trinity College Dublin. He is the National Lead for esophageal and gastric cancer. He is Cancer Lead at St. James’s Hospital and the Trinity School of Medicine, and a Principal Investigator in the Trinity Translational Medicine Institute. He has formerly held Fellowship positions with the University of Pennsylvania and Wistar Institute in Philadelphia and at the Memorial Sloan-Kettering Cancer Centre in New York. He was a Senior Lecturer at St James’s University Hospital in Leeds (1994-6).

Professor Reynolds bas obtained numerous research awards and has published widely in cancer research, with over 250 publications and approximately €5m research grant income. His clinical interest is in diseases of the esophagus and stomach. His research interest is in four areas:

(1) pathogenesis of Barrett’s esophagus and progression; (2) prediction of response and resistance to chemotherapy and radiation therapy; (3) obesity, altered metabolism, and cancer; (4) malnutrition and peri-operative nutrition.

DR PRATEEK SHARMAG A S T R O E N T E R O LO G I S T U N I V E R S I T Y O F K A N S A S

Prateek Sharma completed his Internal Medicine Residency at the Medical College of Wisconsin in Milwaukee and his Gastroenterology Fellowship at the University of Arizona in Tucson. Dr. Sharma has been at the forefront in improving diagnosis and management of gastrointestinal diseases and cancer specifically in advanced imaging and endoscopic treatments. He is a world renowned physician, teacher and educator.

Dr. Sharma has been interviewed by the Wall Street Journal and Newsweek. He has over 400 publications including original articles and book chapters and is regularly invited to present at major national and international meetings. In addition he has also co-edited several important books that are regularly used by doctors and students/residents in training.

Dr. Sharma has and continues to publish in more than 20 high profile journals from the USA and international including the New England Journal of Medicine, Annals of Internal Medicine, Gastrointestinal Endoscopy, Gastroenterology, American Journal of Gastroenterology, to name a few. He is a member of the editorial board of several American and international journals. Dr. Sharma is currently the Vice President of International Society for Diseases of the Esophagus and a Governing Board Member of the American Society for Gastrointestinal endoscopy (ASGE).

Dr. Rebecca K.S. Wong is a radiation oncologist at Princess Margaret Cancer Center; Professor & Vice Chair for Education, Department of Radiation Oncology, University of Toronto. She completed her medical training at University of Sheffield, her Radiation Oncology training at Queen’s University, and Clinical Epidemiology training at McMaster University.

Her clinical and research interests are in gastrointestinal malignancies and palliative radiotherapy. She has served as the CCTG Esophagogastric working group co-chair for 15 and the Symptom Control Chair for 17 years. She is the Canadian Study Chair for the gastric study TOPGEAR. She has over the years served as co-chair to the GI committee for the Cancer Care Ontario Program in Evidence Based Care.

In recent years, her scope of interest has expanded into advancing outcomes through health professional education, both here at home and in the global resource constraint settings. She has authored over 120 peer- reviewed publications, and eight book chapters.

DR REBECCA WONGR A D I AT I O N O N CO LO G I S T U N I V E R S I T Y O F TO R O N TO

PROGRAM

SES

SIO

N I

EA

RLY

NEO

PLA

SIA

AN

D E

ND

OS

CO

PIC

TH

ER

AP

IES

9:25 am CASE PRESENTATIONS

9:45 am REFRESHMENT BREAK & EXHIBITS

8:00 am WELCOME LO R E N ZO F E R R I , M D, P H D S U R G E O N , M CG I L L U N I V E R S I T Y

MODERATORS S E R G E M AY R A N D, M D, G A S T R O E N T E R O LO G I S T, M CG I L L U N I V E R S I T Y

C A R M E N M U E L L E R , M D, M E D, S U R G E O N , M CG I L L U N I V E R S I T Y

8:05 am EARLY NEOPLASIA OF THE FOREGUT ENHANCED IMAGING AND DIAGNOSTIC TECHNIQUES P R AT E E K S H A R M A , M D G A S T R O E N T E R O LO G I S T, U N I V E R S I T Y O F K A N S A S

8:20 am DIAGNOSTIC AND THERAPEUTIC ROLE OF ENDOSCOPIC ULTRASOUND IN GASTRIC CANCER Y E N - I C H E N , M D G A S T R O E N T E R O LO G I S T, M CG I L L U N I V E R S I T Y, M O N T R E A L

8:35 am ENDOSCOPIC RESECTION OF EARLY UPPER GI MALIGNANCY– TECHNIQUES AND OUTCOMES LO R E N ZO F E R R I , M D, P H D S U R G E O N , M CG I L L U N I V E R S I T Y, M O N T R E A L

8:50 am DYSPLASTIC BARRETT’S ESOPHAGUS – WHO AND HOW TO ABLATE? P R AT E E K S H A R M A , M D G A S T R O E N T E R O LO G I S T, U N I V E R S I T Y O F K A N S A S

9:00 am MALIGNANT UPPER GI OBSTRUCTION – WHAT ARE THE OPTIONS FOR OPTIMAL NUTRITIONAL ACCESS IN THE NEOADJUVANT AND PALLIATIVE J O N AT H A N CO O L S - L A R T I G U E, M D, P H D S U R G E O N , M CG I L L U N I V E R S I T Y, M O N T R E A L

9:10 am MINIMALLY INVASIVE ESOPHAGECTOMY LO R E N ZO F E R R I , M D, P H D S U R G E O N , M CG I L L U N I V E R S I T Y, M O N T R E A L

7:30 am BREAKFAST AND REGISTRATION

SE

SS

ION

IILO

CA

LLY

AD

VA

NC

ED

ES

OP

HA

GO

-GA

STR

IC C

AR

CIN

OM

AMODERATORS

J O N AT H A N S P I C E R , M D, P H D, S U R G E O N , M CG I L L U N I V E R S I T Y J OA N N E A L F I E R I , M D, R A D I AT I O N O N CO LO G I S T, M CG I L L U N I V E R S I T Y

10:15 am GASTRECTOMY AND EXTENDED LYMPHADENECTOMY – TECHNIQUE, OUTCOMES, AND IMPACT ON ADJUVANT THERAPY C A R M E N M U E L L E R , M D, M E D S U R G E O N , M CG I L L U N I V E R S I T Y, M O N T R E A L

10:30 am NEOADJUVANT/PERIOPERATIVE THERAPY FOR ESOPHAGEAL AND GASTRIC ADENOCARCINOMA T H I E R R Y A LC I N D O R , M D M E D I C A L O N CO LO G I S T, M CG I L L U N I V E R S I T Y M O N T R E A L

10:45 am MANAGEMENT OF ESOPHAGEAL CANCER: NEOADJUVANT AND DEFINITIVE RADIOTHERAPY R E B E CC A W O N G , M D R A D I AT I O N O N CO LO G I S T, U N I V E R S I T Y O F TO R O N TO

11:00 am EN-BLOC ESOPHAGECTOMY – RATIONAL AND APPROACH N A S S E R A LTO R K I , M D S U R G E O N , CO R N E L L U N I V E R S I T Y, N E W YO R K

11:15 am NEOADJUVANT CHEMOTHERAPY VERSUS CHEMORADIOTHERAPY FOR ESOPHAGEAL ADENOCARCINOMA J O H N R E Y N O L D S , M D S U R G E O N , T R I N I T Y CO L L E G E D U B L I N

11:30 am ESOPHAGO-GASTRIC JUNCTION ADENOCARCINOMA – CLASSIFICATION AND IMPLICATIONS FOR THERAPY J O N AT H A N CO O L S - L A R T I G U E, M D, P H D S U R G E O N , M CG I L L U N I V E R S I T Y, M O N T R E A L

11:45 am UPPER GI TUMOUR BOARD PA N E L D I S C U S S I O N

12:15 pm LUNCH AND EXHIBITS

SES

SIO

N I

II

MA

NA

GE

ME

NT O

F A

DV

AN

CE

D/

CO

MP

LIC

ATE

D E

SO

PH

AG

O- G

ASTR

IC C

AR

CIN

OM

AMODERATORS

T H I E R R Y A LC I N D O R , M D, M E D I C A L O N CO LO G I S T, M CG I L L U N I V E R S I T Y J O N AT H A N CO O L S - L A R T I G U E, M D, P H D, S U R G E O N , M CG I L L U N I V E R S I T Y

1:00 pm METASTATIC ESOPHAGEAL AND GASTRIC CANCER: FIRST LINE, SECOND LINE, AND BEYOND TA N I O S B E K A I I - S A A B, M D M E D I C A L O N CO LO G I S T, M AYO C L I N I C , A R I ZO N A

1:20 pm INDIVIDUALIZED DECISION MAKING BASED ON CHEMORADIATION TREATMENT RESPONSE ASSESSMENT IN ESOPHAGEAL CANCER S T E V E N L I N , M D, P H D R A D I AT I O N O N CO LO G I S T, M D A N D E R S O N C A N C E R C E N T E R , H O U S TO N

1:35 pm STENTING FOR ESOPHAGEAL CANCER – TECHNICAL ISSUES AND OUTCOMES M O I S H E L I B E R M A N , M D, P H D S U R G E O N , U N I V E R S I T É D E M O N T R É A L

1:50 pm PALLIATIVE RADIOTHERAPY FOR ESOPHAGEAL CANCER - WHOM, WHEN, HOW R E B E CC A W O N G , M D R A D I AT I O N O N CO LO G I S T, U N I V E R S I T Y O F TO R O N TO

2:05 pm SALVAGE ESOPHAGECTOMY POST DEFINITIVE CHEMORADIATION WAY N E H O F S T E T T E R , M D R A D I AT I O N O N CO LO G I S T, M D A N D E R S O N C A N C E R C E N T E R , H O U S TO N

2:20 pm PREVENTING AND DOCUMENTING COMPLICATIONS AFTER THORACIC SURGERY A N D R E W S E E LY, M D, P H D S U R G E O N , U N I V E R S I T Y O F OT TAWA

3:00 pm CASE PRESENTATIONS

3:30 pm REFRESHMENT BREAK & EXHIBITS

2:35 pm MANAGEMENT OF COMPLICATIONS AFTER ESOPHAGECTOMY N A S S E R A LTO R K I , M D S U R G E O N , CO R N E L L U N I V E R S I T Y, N E W YO R K

SES

SIO

N IV

R

ES

EA

RC

H ID

EA

S A

ND

NO

VE

L T

EC

HN

OLO

GIE

SMODERATORS

LO R E N ZO F E R R I , M D, P H D, S U R G E O N , M CG I L L U N I V E R S I T Y

4:00 pm INDOCYANINE GREEN TISSUE ANGIOGRAPHY AFFECTS ANASTOMOTIC LEAKAGE AFTER ESOPHAGECTOMY U L R I C H R O N E L L E N F I T S C H , M D, P H D S U R G E O N , H E I D E L B E R G U N I V E R S I T Y, G E R M A N Y

4:10 pmNEUTROPHIL EXTRACELLULAR TRAPS – A NOVEL FUNCTIONAL BIOMARKER FOR THORACIC MALIGNANCIES J O N AT H A N S P I C E R , M D, P H D S U R G E O N , M CG I L L U N I V E R S I T Y, M O N T R E A L

4:20 pm USING PATIENT DERIVED ORGANOIDS AND XENOGRAFTS TO DIRECT PRECISION MEDICINE FOR ESOPHAGEAL CANCER: FRAMEWORK FOR AN UMBRELLA TRIAL V E E N A S A N G WA N , P H D S C I E N T I S T, D I V I S I O N O F T H O R AC I C S U R G E R Y, M CG I L L U N I V E R S I T Y, M O N T R E A L

4:30 pm DETERMINING THE MOLECULAR MEDIATORS OF PROGRESSION TO PERITONEAL METASTASIS FROM GASTRO-ESOPHAGEAL ADENOCARCINOMAS S W N E K E B A I L E Y, P H D S C I E N T I S T, D I V I S I O N O F T H O R AC I C S U R G E R Y, M CG I L L U N I V E R S I T Y, M O N T R E A L

4:40 pm DIFFERENTIAL RESPONSE TO TREATMENT BASED ON GENOMIC AND MOLECULAR PROFILE J O H N R E Y N O L D S , M D S U R G E O N , T R I N I T Y CO L L E G E D U B L I N

6:00 pm COCKTAILS & DINNER L E R I C H M O N D 377 R I C H M O N D AV E N U E M O N T R E A L H 3 J 1 T 9